PL397252A1 - Białko fuzyjne białek regulatorowych i pomocniczych HIV, kwas nukleinowy kodujący to białko, zawierający je wektor, sposób jego wytwarzania, transfekowana komórka gospodarza, szczepionka i ich zastosowanie - Google Patents
Białko fuzyjne białek regulatorowych i pomocniczych HIV, kwas nukleinowy kodujący to białko, zawierający je wektor, sposób jego wytwarzania, transfekowana komórka gospodarza, szczepionka i ich zastosowanieInfo
- Publication number
- PL397252A1 PL397252A1 PL397252A PL39725203A PL397252A1 PL 397252 A1 PL397252 A1 PL 397252A1 PL 397252 A PL397252 A PL 397252A PL 39725203 A PL39725203 A PL 39725203A PL 397252 A1 PL397252 A1 PL 397252A1
- Authority
- PL
- Poland
- Prior art keywords
- proteins
- protein
- fusion protein
- vaccine
- auxiliary
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000001105 regulatory effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200754 | 2002-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL397252A1 true PL397252A1 (pl) | 2012-04-10 |
Family
ID=29433046
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03372092A PL372092A1 (pl) | 2002-05-16 | 2003-05-14 | Białko fuzyjne białek regulatorowych i pomocniczych HIV |
| PL397252A PL397252A1 (pl) | 2002-05-16 | 2003-05-14 | Białko fuzyjne białek regulatorowych i pomocniczych HIV, kwas nukleinowy kodujący to białko, zawierający je wektor, sposób jego wytwarzania, transfekowana komórka gospodarza, szczepionka i ich zastosowanie |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03372092A PL372092A1 (pl) | 2002-05-16 | 2003-05-14 | Białko fuzyjne białek regulatorowych i pomocniczych HIV |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US20050222388A1 (pl) |
| EP (2) | EP1506223B1 (pl) |
| JP (3) | JP2006502704A (pl) |
| KR (4) | KR100996330B1 (pl) |
| CN (3) | CN1325512C (pl) |
| AT (2) | ATE407143T1 (pl) |
| AU (2) | AU2003240638B2 (pl) |
| BR (1) | BR0309963A (pl) |
| CA (1) | CA2483640A1 (pl) |
| CY (1) | CY1108638T1 (pl) |
| DE (2) | DE60302356T2 (pl) |
| DK (2) | DK1652857T3 (pl) |
| EA (1) | EA007154B1 (pl) |
| ES (2) | ES2253675T3 (pl) |
| IL (3) | IL164178A0 (pl) |
| MX (1) | MXPA04010683A (pl) |
| NO (1) | NO20045229L (pl) |
| NZ (2) | NZ536499A (pl) |
| PL (2) | PL372092A1 (pl) |
| PT (1) | PT1652857E (pl) |
| SI (2) | SI1506223T1 (pl) |
| UA (3) | UA82998C2 (pl) |
| WO (1) | WO2003097675A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| KR100996330B1 (ko) * | 2002-05-16 | 2010-11-23 | 버베리안 노딕 에이/에스 | Ｈｉｖ 조절/부속 단백질의 융합 단백질 |
| CA2519025A1 (en) | 2003-03-28 | 2004-10-07 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services, Centers For Disea | Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use |
| AU2006304392B2 (en) * | 2005-10-18 | 2014-05-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
| EP2044224A4 (en) * | 2006-07-27 | 2011-04-13 | Ligocyte Pharmaceuticals Inc | CHIMERIC VIRUS TYPE PARTICLES |
| US9439959B2 (en) | 2006-07-27 | 2016-09-13 | Takeda Vaccines, Inc. | Chimeric influenza virus-like particles |
| SG10201803982TA (en) | 2008-05-16 | 2018-07-30 | Taiga Biotechnologies Inc | Antibodies and processes for preparing the same |
| AU2009274172B2 (en) | 2008-07-21 | 2015-08-13 | Htyr Acquisition Llc | Differentiated anucleated cells and method for preparing the same |
| EP2966084B1 (en) | 2008-08-28 | 2018-04-25 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same and methods of identifying agents that modulate myc |
| KR20120093941A (ko) * | 2009-10-08 | 2012-08-23 | 버베리안 노딕 에이/에스 | 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성 |
| EP2485759A4 (en) * | 2009-10-09 | 2013-07-24 | Univ New York | METHOD, AGENTS AND PEPTIDES FOR GENERATING A BORN IMMUNE RESPONSE IN HIV VACCINATION |
| CN102753582A (zh) | 2009-11-03 | 2012-10-24 | 莱戈赛特医药股份有限公司 | 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| CN110643576A (zh) | 2012-07-20 | 2020-01-03 | 泰加生物工艺学公司 | 造血区室的增强的重建和自动重建 |
| US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| US10196426B1 (en) | 2014-06-18 | 2019-02-05 | Sun Yat-Sen University | Chimeric vector and preparation method and use thereof |
| CN104130331B (zh) * | 2014-06-19 | 2017-06-06 | 中山大学 | 一种抗hiv‑1病毒药物及其制备和应用 |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| CN105330729A (zh) * | 2015-11-18 | 2016-02-17 | 南京医科大学 | 一种人类免疫缺陷病毒Vpr蛋白的制备方法 |
| US10583156B2 (en) | 2016-12-02 | 2020-03-10 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| CN113874033A (zh) | 2019-04-08 | 2021-12-31 | 泰加生物工艺学公司 | 用于冷冻保存免疫细胞的组合物和方法 |
| JP2022532608A (ja) | 2019-05-14 | 2022-07-15 | タイガ バイオテクノロジーズ，インク． | Ｔ細胞疲弊を処置するための組成物および方法 |
| CN116322757A (zh) | 2019-11-14 | 2023-06-23 | 埃利克斯疗法公司 | 用于疫苗的剂量方案 |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4088697A (en) * | 1996-08-26 | 1998-03-19 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
| GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
| IT1297090B1 (it) | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
| FR2773156B1 (fr) * | 1997-12-26 | 2000-03-31 | Biovacs Inc | Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida |
| FI105105B (fi) | 1998-02-27 | 2000-06-15 | Finnish Immunotechnology Ltd O | Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| CA2398611A1 (en) | 2000-01-31 | 2001-08-02 | Smithkline Beecham Biologicals S.A. | Vaccine for the prophylactic or therapeutic immunization against hiv |
| EP1418940A4 (en) * | 2000-03-02 | 2006-09-20 | Univ Emory | DNA EXPRESSION VECTORS AND METHODS OF USE |
| US6544780B1 (en) * | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
| JP2004525604A (ja) * | 2000-07-14 | 2004-08-26 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | Ｈｉｖアクセサリータンパク質をコードするｄｎａワクチン |
| ES2386884T3 (es) * | 2000-11-01 | 2012-09-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vectores de expresión capaces de inducir respuesta inmunomejorada y métodos para usarlos |
| US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| KR100996330B1 (ko) * | 2002-05-16 | 2010-11-23 | 버베리안 노딕 에이/에스 | Ｈｉｖ 조절/부속 단백질의 융합 단백질 |
-
2003
- 2003-05-14 KR KR1020047017968A patent/KR100996330B1/ko not_active Expired - Fee Related
- 2003-05-14 AT AT05017695T patent/ATE407143T1/de active
- 2003-05-14 CN CNB038111195A patent/CN1325512C/zh not_active Expired - Fee Related
- 2003-05-14 DK DK05017695T patent/DK1652857T3/da active
- 2003-05-14 AT AT03730029T patent/ATE310016T1/de active
- 2003-05-14 ES ES03730029T patent/ES2253675T3/es not_active Expired - Lifetime
- 2003-05-14 NZ NZ536499A patent/NZ536499A/en not_active IP Right Cessation
- 2003-05-14 CN CNA2007101039526A patent/CN101108882A/zh active Pending
- 2003-05-14 PT PT05017695T patent/PT1652857E/pt unknown
- 2003-05-14 EP EP03730029A patent/EP1506223B1/en not_active Expired - Lifetime
- 2003-05-14 MX MXPA04010683A patent/MXPA04010683A/es active IP Right Grant
- 2003-05-14 UA UA20041109410A patent/UA82998C2/ru unknown
- 2003-05-14 PL PL03372092A patent/PL372092A1/pl not_active IP Right Cessation
- 2003-05-14 EP EP05017695A patent/EP1652857B9/en not_active Expired - Lifetime
- 2003-05-14 DE DE60302356T patent/DE60302356T2/de not_active Expired - Lifetime
- 2003-05-14 CN CNA200710000639XA patent/CN1982332A/zh active Pending
- 2003-05-14 UA UAA200811374A patent/UA92788C2/ru unknown
- 2003-05-14 EA EA200401504A patent/EA007154B1/ru not_active IP Right Cessation
- 2003-05-14 KR KR1020107008995A patent/KR20100063126A/ko not_active Ceased
- 2003-05-14 ES ES05017695T patent/ES2313166T3/es not_active Expired - Lifetime
- 2003-05-14 CA CA002483640A patent/CA2483640A1/en not_active Abandoned
- 2003-05-14 US US10/514,740 patent/US20050222388A1/en not_active Abandoned
- 2003-05-14 UA UA20041109408A patent/UA85373C2/ru unknown
- 2003-05-14 DE DE60323407T patent/DE60323407D1/de not_active Expired - Lifetime
- 2003-05-14 PL PL397252A patent/PL397252A1/pl not_active Application Discontinuation
- 2003-05-14 JP JP2004506348A patent/JP2006502704A/ja active Pending
- 2003-05-14 DK DK03730029T patent/DK1506223T3/da active
- 2003-05-14 BR BR0309963-6A patent/BR0309963A/pt not_active IP Right Cessation
- 2003-05-14 WO PCT/EP2003/005039 patent/WO2003097675A1/en not_active Ceased
- 2003-05-14 KR KR1020127021229A patent/KR20120106894A/ko not_active Ceased
- 2003-05-14 NZ NZ556144A patent/NZ556144A/en not_active IP Right Cessation
- 2003-05-14 AU AU2003240638A patent/AU2003240638B2/en not_active Ceased
- 2003-05-14 SI SI200330168T patent/SI1506223T1/sl unknown
- 2003-05-14 IL IL16417803A patent/IL164178A0/xx active IP Right Grant
- 2003-05-14 KR KR1020117017944A patent/KR101196178B1/ko not_active Expired - Fee Related
- 2003-05-14 SI SI200331443T patent/SI1652857T1/sl unknown
-
2004
- 2004-09-21 IL IL164178A patent/IL164178A/en not_active IP Right Cessation
- 2004-11-29 NO NO20045229A patent/NO20045229L/no not_active Application Discontinuation
-
2006
- 2006-07-18 US US11/488,803 patent/US7569228B2/en not_active Expired - Fee Related
-
2008
- 2008-12-03 CY CY20081101401T patent/CY1108638T1/el unknown
- 2008-12-04 AU AU2008252074A patent/AU2008252074B2/en not_active Ceased
-
2009
- 2009-02-26 IL IL197304A patent/IL197304A0/en unknown
- 2009-05-11 JP JP2009114359A patent/JP2009178165A/ja active Pending
- 2009-06-24 US US12/490,424 patent/US8143054B2/en not_active Expired - Fee Related
- 2009-11-03 US US12/611,164 patent/US8147839B2/en not_active Expired - Fee Related
- 2009-11-03 US US12/611,188 patent/US8137931B2/en not_active Expired - Fee Related
- 2009-12-22 JP JP2009290256A patent/JP2010099084A/ja active Pending
-
2012
- 2012-02-14 US US13/372,723 patent/US8435535B2/en not_active Expired - Fee Related
- 2012-02-14 US US13/372,706 patent/US8389275B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL397252A1 (pl) | Białko fuzyjne białek regulatorowych i pomocniczych HIV, kwas nukleinowy kodujący to białko, zawierający je wektor, sposób jego wytwarzania, transfekowana komórka gospodarza, szczepionka i ich zastosowanie | |
| WO2007149491A3 (en) | Soluble stabilized trimeric hiv env proteins and uses thereof | |
| NO902251L (no) | Fremstilling av gonoreiske p1-proteiner og vaksiner. | |
| UY23445A1 (es) | Procedimiento para la preparacion de vacunas contra la coccidiosis | |
| ES2009588A6 (es) | Un metodo para la preparacion de un polipeptido. | |
| DE69231705D1 (de) | Gag-Env Fusion-Antigen aus HIV | |
| FR2829498B1 (fr) | Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins | |
| WO2003029285A3 (en) | Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections | |
| DK27097A (da) | Minactivin og fremgangsmåde til fremstilling deraf | |
| WO2004045548A3 (en) | Genetic constructs and compositions comprising rre and cte and uses thereof | |
| GB2336844A (en) | Anti-hiv peptides and proteins | |
| WO2005047483A3 (en) | Renta: an hiv immunogen and uses thereof | |
| GB0325011D0 (en) | HIV pharmaccines | |
| EP0392820A3 (en) | Plasmodium circumsporozoite protein analogs lacking repeat sequences | |
| WO1994029472A3 (en) | Mengovirus as a vector for expression of foreign polypeptides | |
| RU2335540C1 (ru) | ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pBMC-nef(A)-hum | |
| WO2005103302A3 (en) | Mutant viral nucleic acids and vaccine containing same | |
| WO2020144355A3 (fr) | Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre | |
| WO2002068464A3 (de) | Fusionsprotein zum blocken des hiv nef-proteins | |
| WO2004046168A3 (en) | Recombinant hiv-1 subclass d envelope glycoproteins | |
| TH78666A (th) | วัคซีนรีคอมบิแนนท์แวคซิเนียไวรัส |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |